Summaries for Patients |

A New Anti-Inflammatory Therapy (Infliximab) for Complicated Sarcoidosis FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full report titled “Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α Therapy.” It is in the 3 July 2001 issue of Annals of Internal Medicine (volume 135, pages 27-31). The authors are AMF Yee and MB Pochapin.

Ann Intern Med. 2001;135(1):S20. doi:10.7326/0003-4819-135-1-200107030-00009
Text Size: A A A

What is the problem and what is known about it so far?

Sarcoidosis is a disease of unknown cause that produces chronic inflammation in many different organs of the body. The disease can appear in several ways, but it most often damages the lungs. Tissue samples from patients with sarcoidosis show a typical appearance under a microscope. Although mild cases of the disease frequently get better without treatment, severe cases often require treatment with corticosteroid medications. Inflammation in sarcoidosis involves the accumulation of tiny collections of cells (known as noncaseating granulomas) throughout the affected tissue. One of the cell types in these granulomas is known as a macrophage. Macrophages produce a chemical called tumor necrosis factor-α (TNF-α) that may accelerate the inflammatory process. Corticosteroids decrease the production of TNF-α. Unfortunately, corticosteroid treatment does not always work and may have many toxic side effects. Alternative treatments for sarcoidosis would therefore be very helpful. A new pharmaceutical agent, infliximab, is a human-made antibody (antibodies are substances that the body usually uses to fight off infection) that specifically blocks the effect of TNF-α.

Why did the researchers do this particular study?

The researchers wanted to see if infliximab could be used effectively to treat a patient with sarcoidosis who did not respond to corticosteroids.

Who was studied?

A 72-year-old woman with severe diarrhea, nodules in her lungs, enlarged lymph nodes, and abnormalities in her muscles. The patient underwent biopsies, and the tissue samples showed changes in tissue appearance that are typical of sarcoidosis. Despite corticosteroid therapy, the patient's illness got worse.

How was the study done and what did the researchers find?

Nine months after the onset of her illness, after corticosteroids had failed to produce improvement, the patient was given a dose of infliximab. Within 2 days, the woman's muscle strength increased, and within 1 week, her diarrhea improved; the lung nodules went away completely. However, after the third dose of infliximab, abnormal blood clots formed. Although it was unclear whether infliximab contributed to this complication, the therapy was discontinued. Soon afterward, soft bowel movements returned. The patient then received another drug (thalidomide) that relieved her symptoms.

What were the limitations of the study?

Only one patient was studied, and she did not have the typical clinical pattern of sarcoidosis (which usually affects the lung more than the bowel). Infliximab seems to have worked through its action against TNF-α; however, the authors cannot be certain of this.

What are the implications of the study?

Infliximab may be useful in treating sarcoidosis that does not respond to corticosteroid therapy.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.